If I had $10,000 to invest in ASX growth shares, I'd be looking for companies with plenty of room to expand and the financial strength to make the most of their opportunities.
With that in mind, here are three ASX growth shares I'd happily consider buying for the future.
The first ASX growth share I'd consider is Breville, which has built a successful global business selling premium coffee machines and kitchen appliances.
And I believe its international expansion is only getting started. Breville is still developing its presence in major markets such as China, Korea, Mexico, and the Middle East.
In FY 2026, sales across these newer markets grew by more than 70% collectively. Admittedly, that's from a relatively small base, but it demonstrates how much room the business has to expand.
I also like management's long-term (and ongoing) decision to invest around 14% of sales back into research and development, marketing, and technology activities. This ensures that Breville has a pipeline of innovative products that help it generate more revenue in established markets and break into new ones.
Although currency movements and tariffs have weighed on its profitability recently, I believe Breville's strong brands and international opportunities could support material earnings growth over the next decade.
Another ASX growth share I'd consider buying is CAR Group, which is best known for its carsales.com.au marketplace in Australia.
However, it also operates leading vehicle marketplaces in South Korea, Brazil, and North America. And I think these international businesses could become increasingly important to its growth.
In FY 2026, CAR Group reported a 12% increase in pro forma revenue in constant currency, with Latin America delivering particularly strong growth of 19%.
What I like about the company is that it can increase revenue without necessarily needing more vehicles to be sold. As dealers adopt premium advertising, data products, and other services, CAR Group can generate additional revenue from its existing customers.
And with its marketplaces already attracting large audiences, it has a strong competitive position that would be difficult for newcomers to replicate.
I believe these competitive advantages could help CAR Group deliver strong earnings growth over the coming years.
Finally, I'd consider sleep treatment giant ResMed as an ASX growth share to buy with the $10,000.
The company develops devices and masks that help people manage obstructive sleep apnoea, which is a condition that remains significantly underdiagnosed around the world.
As awareness improves and more people seek treatment, I believe ResMed has an enormous opportunity to expand its customer base.
And there's another element to its business model that I really like. Once patients begin treatment, they typically need replacement masks and other accessories regularly. This creates a valuable stream of recurring revenue alongside sales of new devices.
With its market-leading position, strong cash generation, and opportunities to reach millions of additional patients over the next decade, I believe ResMed could be a fantastic long-term investment.
The post Where I'd invest $10,000 in ASX growth shares appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CAR Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026